Quick Answer
Without insurance, brand-name semaglutide costs roughly $968 to $1,349 per month at US retail as of July 2026 (manufacturer list prices): Wegovy about $1,349, Ozempic about $968 to $1,150, Rybelsus about $1,029. Eligible cash-pay patients can get Wegovy for about $499 per month through Novo Nordisk's NovoCare program.
Separately, compounded semaglutide through US-licensed telehealth is a cash-pay category of its own, typically $179 the first month and $249 to $399 per month after, all-in. Compounded semaglutide is not FDA-approved as a final product and is not a generic version of, equivalent to, or interchangeable with any brand-name medication.
The Real Numbers (July 2026)
Manufacturer list prices at US retail, as of July 2026; verify at point of purchase, pricing changes:
| Product | Form | Cash price per month | FDA-approved indication |
|---|---|---|---|
| Wegovy (Novo Nordisk) | Weekly injection pen | ~$1,349 | Chronic weight management; cardiovascular risk reduction in adults with CVD and overweight or obesity |
| Ozempic (Novo Nordisk) | Weekly injection pen | ~$968 to $1,150 | Type 2 diabetes (often prescribed off-label for weight loss) |
| Rybelsus (Novo Nordisk) | Daily oral tablet | ~$1,029 | Type 2 diabetes |
| Compounded semaglutide (US telehealth market) | Weekly injection, vial and syringe | $179 first month, then $249 to $399 | Not FDA-approved as a final product; prescribed per-patient by a licensed physician |
That top-line gap is the whole story of this topic: without coverage, a year of Wegovy at list price is over $16,000. Most people searching "semaglutide cost without insurance" are really asking which of the legitimate cheaper paths fits them.
Why the Price Is So High
Semaglutide is still under patent protection in the US, so there is no true generic. The brand price reflects the original development and trial programs, FDA approval, manufacturing, and marketing, without generic competition. None of that is a scandal by itself; it is simply why the cash price and the insured copay live in different universes.
The problem is that insurance coverage for the weight-management indication is inconsistent. Many employer plans exclude weight-loss medications entirely, and plans that do cover Wegovy usually require prior authorization with documented BMI and comorbidity criteria. Coverage of Ozempic is broader but tied to a type 2 diabetes diagnosis.
Path 1: Manufacturer Savings Programs
If you want the FDA-approved brand product, check Novo Nordisk's programs first (terms as of July 2026; verify current details at NovoCare):
At $499 per month, brand-name Wegovy costs about $5,988 per year for eligible cash payers, roughly a third of list price, for the fully FDA-approved product with pen delivery.
Path 2: Compounded Semaglutide
Compounded semaglutide is the route most cash payers land on, and it deserves an honest description.
It contains semaglutide as its active pharmaceutical ingredient, meeting United States Pharmacopeia (USP) standards. It is prepared by a state-licensed compounding pharmacy (section 503A) under an individual prescription written by a licensed physician for you specifically. It is not FDA-approved as a final product and is not a generic version of, equivalent to, or interchangeable with any brand-name medication.
Typical all-in telehealth pricing in 2026 is $179 the first month and $249 to $399 per month after. At Majesta Health:
Both plans include the physician consultation, the medication, shipping, and ongoing physician messaging, with no prepay and cancellation anytime. Our physicians are listed on the care team page. For the provider-by-provider market table, see the compounded semaglutide cost breakdown.
The 12-Month Math
For the brand routes, here is the annual arithmetic at prices as of July 2026, assuming monthly billing:
| Brand option | Month 1 | Months 2-12 | 12-month total |
|---|---|---|---|
| Wegovy at list price | $1,349 | $1,349 × 11 = $14,839 | ~$16,188 |
| Wegovy cash-pay program (eligible patients) | $499 | $499 × 11 = $5,489 | ~$5,988 |
Compounded programs are billed as their own bundled monthly cash amounts; for Majesta plans, see our billing policy for exact cycle details before running annual totals. Treatment duration is a clinical decision made with your physician, not a package to pre-buy.
HSA, FSA, and Taxes
Prescription semaglutide is generally HSA- and FSA-eligible with valid documentation, whether brand-name or compounded. Save your prescription confirmation and receipts, and confirm requirements with your plan administrator.
How to Decide
A fair rule of thumb:
Whichever route you consider, the decision of whether semaglutide is appropriate for you at all belongs to a licensed physician after reviewing your health history. Price is the second question, not the first. For more on how compounded semaglutide is regulated and priced, see our compounded semaglutide guide, and for the whole GLP-1 class, our GLP-1 cost without insurance guide.
The Bottom Line
Without insurance, brand-name semaglutide at list price costs about $968 to $1,349 per month as of July 2026, and Novo Nordisk's cash-pay Wegovy program brings that to roughly $499 per month for eligible patients. Compounded semaglutide through licensed telehealth is a separate cash-pay category at $179 the first month and $249 to $399 per month after, all-in. Know all three numbers, and your documented coverage, before you pay any of them.
If you want a physician's read on whether semaglutide treatment makes sense for you, start with the 2-minute medical assessment.
Take the 2-minute medical assessment →
Related guides
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider. Compounded medications are not FDA-approved as final products. Prices reflect published US pricing as of July 2026 and are subject to change. Individual results may vary.
Frequently Asked Questions
How much does semaglutide cost per month without insurance?
Brand-name semaglutide costs roughly $968 to $1,349 per month at US retail without insurance as of July 2026 (manufacturer list prices): Wegovy is about $1,349, Ozempic about $968 to $1,150, and Rybelsus about $1,029. Eligible cash-pay patients can get Wegovy for about $499 per month through Novo Nordisk's direct-to-patient program. Compounded semaglutide through US-licensed telehealth typically runs $179 the first month and $249 to $399 per month after; compounded preparations are not FDA-approved as final products.
Why is semaglutide so expensive without insurance?
Semaglutide is still under patent, so no true generic exists in the US. The list price carries the cost of the original clinical trial programs (such as STEP for Wegovy), FDA approval, manufacturing, and marketing, with no generic competition to push prices down. Insurance normally absorbs much of that for covered indications, which is why the uninsured cash price feels so far out of line with copays.
What is the cheapest way to get semaglutide without insurance?
Two legitimate routes are worth pricing out in 2026. Novo Nordisk's cash-pay Wegovy program offers the FDA-approved brand product at about $499 per month for eligible patients. Separately, compounded semaglutide through a US-licensed telehealth provider is a cash-pay program typically running $179 the first month and $249 to $399 per month after, all-in; compounded semaglutide is not FDA-approved as a final product and is not a generic version of, or interchangeable with, any brand product. A licensed physician should help you weigh the routes, and if your insurance covers a brand product, that may be the better option.
Does Novo Nordisk offer discounts on Wegovy or Ozempic?
Yes. As of July 2026, NovoCare offers a direct-to-patient cash-pay program for Wegovy at about $499 per month for eligible patients, plus copay savings cards for commercially insured patients that can significantly reduce out-of-pocket costs when coverage exists. Eligibility rules apply to both, and programs change; verify current terms on NovoCare's site before planning around them.
Is compounded semaglutide as effective as brand-name Wegovy?
There are no head-to-head clinical trials comparing compounded semaglutide with any brand product, so no one can honestly claim equivalent results. Brand-name efficacy was established in FDA-supervised trials of the brand products; no trial has evaluated compounded preparations. Compounded semaglutide contains semaglutide meeting USP standards, but it is not FDA-approved as a final product and is not a generic version of, equivalent to, or interchangeable with any brand-name medication. Individual results vary and are set with your physician.
Can I pay for semaglutide with HSA or FSA funds?
Typically yes. Prescription semaglutide, brand-name or compounded, is generally an eligible medical expense when you have a valid prescription. Keep your prescription confirmation and receipts, and confirm the details with your HSA or FSA plan administrator, since administrators set their own documentation requirements.
Majesta Health medical content is written against primary sources (FDA labels, peer-reviewed trials, HHS and CDC publications) and passes a documented compliance review before publication. We are rolling out named physician review with US-licensed clinicians from our partner MD Integrations (MDI): each reviewed article will show the reviewing physician's name, NPI, and review date. MDI is LegitScript certified and SOC 2 Type II accredited.
- US-licensed physicians affiliated with our clinical partner MD Integrations (LegitScript certified, HIPAA, SOC 2 Type II, ISO certified)
- Board-certified in primary care and obesity medicine
- Active state medical licensure required for every prescribing clinician
- Active DEA registration where applicable (note: GLP-1 medications are not controlled substances)
- Telehealth practice across the states we currently serve through the MD Integrations Medical Services Organization (coverage varies by state; see our states page)
- Dispensing pharmacy partner: Belmar Pharma Solutions (LegitScript certified, NABP accredited); Majesta prescriptions are dispensed through Belmar's state-licensed 503A compounding pharmacy